Kiora Pharmaceuticals Inc SEC filings KPHMW
Kiora Pharmaceuticals Inc has 926 filings in SEC EDGAR's recent list, going back to Aug 9, 2006. Its latest annual report, Form ARS, was filed on May 1, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 7, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 29, 2026 (material agreement, regulation fd disclosure). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| DEF 14A | Proxy statement | Apr 30, 2026 | Apr 16, 2026 |
| DEF 14A | Proxy statement | Apr 30, 2025 | Apr 16, 2025 |
| DEF 14A | Proxy statement | Mar 25, 2024 | May 1, 2024 |
| PRE 14A | Preliminary proxy statement | Mar 15, 2024 | May 1, 2024 |
| DEFA14A | Additional proxy material | Sep 1, 2023 | — |
| DEF 14A | Proxy statement | Jul 21, 2023 | Aug 31, 2023 |
| PRE 14A | Preliminary proxy statement | Jul 11, 2023 | Aug 31, 2023 |
| DEF 14A | Proxy statement | Apr 28, 2023 | Jun 21, 2023 |
| DEF 14A | Proxy statement | Aug 15, 2022 | Sep 23, 2022 |
| DEF 14A | Proxy statement | Aug 8, 2022 | Sep 15, 2022 |
| PRE 14A | Preliminary proxy statement | Aug 5, 2022 | Sep 23, 2022 |
| PRE 14A | Preliminary proxy statement | Jul 27, 2022 | Sep 15, 2022 |
| DEFA14A | Additional proxy material | Apr 30, 2021 | — |
| DEF 14A | Proxy statement | Apr 30, 2021 | Jun 24, 2021 |
| PRE 14A | Preliminary proxy statement | Apr 20, 2021 | Apr 20, 2021 |
| DEFA14A | Additional proxy material | Apr 29, 2020 | — |
| DEF 14A | Proxy statement | Apr 29, 2020 | Jun 25, 2020 |
| PRE 14A | Preliminary proxy statement | Apr 17, 2020 | Jun 25, 2020 |
| DEFA14A | Additional proxy material | May 2, 2019 | — |
| DEF 14A | Proxy statement | Apr 30, 2019 | Jun 20, 2019 |
| PRE 14A | Preliminary proxy statement | Apr 19, 2019 | Jun 20, 2019 |
| DEFA14A | Additional proxy material | Jul 3, 2018 | — |
| DEFA14A | Additional proxy material | May 29, 2018 | — |
| DEF 14A | Proxy statement | May 29, 2018 | Jul 10, 2018 |
| PRE 14A | Preliminary proxy statement | May 17, 2018 | Jul 10, 2018 |
| DEFA14A | Additional proxy material | Apr 28, 2017 | — |
| DEF 14A | Proxy statement | Apr 28, 2017 | Jun 21, 2017 |
| DEFA14A | Additional proxy material | Apr 28, 2016 | — |
| DEF 14A | Proxy statement | Apr 28, 2016 | Jun 21, 2016 |
Showing 29 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- KPRX (Nasdaq), KPHMW (OTC)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Encinitas, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1372514
- Former names
- EYEGATE PHARMACEUTICALS INC (until Nov 4, 2021)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.